The syndrome of sensory neuronopathy and detection of anti-Hu antibody in 2010 were very strong indications of the presence of a malignant tumour. In a series of 200 patients positive for anti-Hu, 83.5 percent were found to have cancer, and 90 percent of the cancer cases were small-cell lung cancer.
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
A 73-year-old man presented with 1 week’s history of progressive epigastric pain. The pain was dull in nature and the patient reported no vomiting or radiation of pain. On presentation, the patient was found to have a low-grade fever (temperature, 37.8°C). There was no tea-coloured urine. The patient had enjoyed good past health except for a previous surgery for spinal injury.
Krukenberg tumour is a metastatic signet ring cell adenocarcinoma of the ovary. This tumour is uncommon, accounting for 1–2% of all ovarian tumours. The stomach is the primary site in most Krukenberg tumour cases (70%), and the prognosis is generally poor. We report a case of a pregnant lady who was incidentally found to have a large ovarian mass during caesarean section which was later confirmed to be a Krukenberg tumour.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.
A second set of Choosing Wisely recommendations developed by the American Society of Hematology (ASH) were presented at the 56th ASH Annual Meeting & Exposition. The following list adds to the previous five tests, treatments and procedures that should be questioned by clinicians and patients under specific, indicated circumstances. [Blood 2014;124:3524-3528]
The US FDA granted accelerated approval to palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, as first-line endocrine therapy for postmenopausal women with oestrogen receptor (ER)-positive, HER2-negative metastatic breast cancer.